Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients.
复制标题
DOI：
10.1016/j.ccell.2021.01.001
复制
发表时间：
2021-02-08
期刊：
影响因子：
50.3
通讯作者：
Irshad S
中科院分区：
文献类型：
--
作者：
Abdul-Jawad S;Baù L;Alaguthurai T;Del Molino Del Barrio I;Laing AG;Hayday TS;Monin L;Muñoz-Ruiz M;McDonald L;Francos Quijorna I;McKenzie D;Davis R;Lorenc A;Chan JNE;Ryan S;Bugallo-Blanco E;Yorke R;Kamdar S;Fish M;Zlatareva I;Vantourout P;Jennings A;Gee S;Doores K;Bailey K;Hazell S;De Naurois J;Moss C;Russell B;Khan AA;Rowley M;Benjamin R;Enting D;Alrifai D;Wu Y;Zhou Y;Barber P;Ng T;Spicer J;Van Hemelrijck M;Kumar M;Vidler J;Lwin Y;Fields P;Karagiannis SN;Coolen ACC;Rigg A;Papa S;Hayday AC;Patten PEM;Irshad S
鉴于免疫系统对癌症监测和治疗的重要性，我们研究了SARS-CoV-2感染对癌症患者免疫系统的影响。在肿瘤类型、分期和治疗的一些异质性中，病毒暴露的实体癌患者显示出SARS-CoV-2的主要影响，这从他们的免疫特征与COVID-19+非癌症患者的相似性中显而易见。血液恶性肿瘤的情况并非如此，病毒暴露患者共同表现出异质性体液应答、耗尽的T细胞表型和长期病毒脱落的高患病率。此外，虽然恢复的实体癌患者的免疫表型类似于非病毒暴露的癌症患者的免疫表型，但恢复的血液学癌症患者显示出独特的、挥之不去的免疫学遗产。因此，虽然实体癌患者，包括那些患有晚期疾病的患者，似乎没有比一般人群更容易发生SARS-CoV-2相关的免疫失调，但血液癌症患者显示出SARS-CoV-2暴露的复杂免疫后果，这可能有助于他们的护理。在SARS-Cov-2感染后，苏丹等人研究表明，大多数实体癌患者清除了病毒，从COVID-19中康复，并重新建立了他们之前的免疫状态。相比之下，血液癌症患者表现出延迟或可忽略的血清转化、延长的脱落和持续的免疫失调，突出了对这些患者进行仔细监督的必要性。
Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care. Following SARS-Cov-2 infection, Sultan et al. showed that the majority of solid cancer patients cleared virus, recovered from COVID-19, and re-established their prior immunological status. In contrast, hematological cancer patients demonstrated delayed or negligible seroconversion, prolonged shedding, and sustained immune dysregulation highlighting the need for careful oversight of these patients.
登录
查看更多内容
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F
影响因子：
12.7
作者：
Chen, Jiangnan;Pan, Yong;Zhang, Jun
通讯作者：
Zhang, Jun
影响因子：
82.9
作者：
He, Xi;Lau, Eric H. Y.;Leung, Gabriel M.
通讯作者：
Leung, Gabriel M.
影响因子：
7.3
作者：
Diao, Bo;Wang, Chenhui;Chen, Yongwen
通讯作者：
Chen, Yongwen
DOI：
10.1084/jem.187.9.1383
发表时间：
1998-05-04
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Gallimore A;Glithero A;Godkin A;Tissot AC;Plückthun A;Elliott T;Hengartner H;Zinkernagel R
通讯作者：
Zinkernagel R